News

Melanonychia Striata Warrants Biopsy in Most Cases

Publish date: October 18, 2010

 

Dr. Scher said that he had no relevant conflicts to disclose.

Pages

Recommended Reading

PARP Inhibitor Adds Nearly 5 Months to Breast Cancer Survival
MDedge Internal Medicine
What Is the Best Approach for High-Risk or Inoperable NSCLC?
MDedge Internal Medicine
Bevacizumab Confirmed Beneficial For First-Line Ovarian Cancer Treatment
MDedge Internal Medicine
Early Results Show Low Toxicity from 3-D Breast Cancer Radiation
MDedge Internal Medicine
Anastrozole Tops Tamoxifen in Decade-Long Analysis of ATAC Trial
MDedge Internal Medicine
Topical 'Smoothened' Inhibitor Promising for Multiple BCCs
MDedge Internal Medicine
FDA Warns About Unapproved OTC Chelation Products
MDedge Internal Medicine
Vascular Invasion Predictive of Poor Prognosis in Thyroid Cancer
MDedge Internal Medicine
CDC Names Members to Advisory Committee on Breast Cancer in Young Women
MDedge Internal Medicine
Perspective: Evaluating Genetic Risk for Breast Cancer
MDedge Internal Medicine